Nick Leschly, partner of Third Rock Ventures, has been appointed the company's president and chief executive as Genetix Pharmaceuticals rebrands itself Bluebird Bio.
Genetix Pharmaceuticals, a US-based biotechnology company, has changed its name to Bluebird Bio and made one of its venture capital (VC) investors executive president.
Nick Leschly, partner of Third Rock Ventures, has been appointed the company’s president and chief executive. He was made interim president of Bluebird in March at the close of the company’s undersubscribed series B round that was reported to have closed at $35m, above that shown in the regulatory filing.
Third Rock led the B…
